Monte Rosa Therapeutics, Inc. 8K

Monte Rosa Therapeutics reported Q2 2026 results, activated key Phase 2 trials for MRT-8102, MRT-6160, and MRT-2359, and indicated its $626 million cash position should fund operations into 2029 despite a higher quarterly net loss.

On August 6, 2026, Monte Rosa Therapeutics, Inc. reported its financial results for the quarter ended June 30, 2026 and provided business updates, highlighting completion of enrollment and dosing in the GFORCE-1 Phase 1 study of MRT-8102 for patients with elevated cardiovascular disease risk and plans to initiate multiple Phase 2 trials of MRT-8102 across atherosclerotic risk, gout, and hidradenitis suppurativa starting in the second half of 2026. The company also disclosed the activation by Novartis of a Phase 2 study of MRT-6160 (DDY391) in Sjögren’s disease under their global license and collaboration agreement—triggering expected milestone payments and outlining potential total milestones up to $2.1 billion—as well as the activation of the MODeFIRe-1 Phase 2 study of MRT-2359 in combination with apalutamide in metastatic castration-resistant prostate cancer patients with AR mutations. Monte Rosa reported second quarter 2026 collaboration revenue of $9.0 million (down from $23.2 million a year earlier), R&D expenses of $48.0 million, G&A expenses of $10.1 million, and a net loss of $43.4 million, and stated it held $626.0 million in cash, cash equivalents, restricted cash, and marketable securities as of June 30, 2026, which it expects will fund operations into 2029.

Filing Facts

CIK

1826457

Ticker

GLUE

Form

8K

Source Type

fda

Accession

0001193125-26-336681

Alert Tier

6